As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The AURA Division of Hetero Healthcare offers a focused portfolio of therapeutic solutions addressing women’s health, reproductive health, hormonal care, nutritional support, and related clinical needs. The division is committed to supporting women through different stages of life by addressing healthcare requirements that may evolve from reproductive years to broader wellness needs.
Its therapeutic portfolio supports healthcare professionals in managing a range of gynaecological and reproductive health concerns, complemented by nutritional and supportive therapies that contribute to overall well-being. By bringing together targeted treatment options within a focused portfolio, AURA aims to enable a more comprehensive approach to women’s healthcare.
Driven by Hetero Healthcare’s focus on quality, patient-centricity, and accessible healthcare, the AURA Division strives to provide dependable therapeutic options for everyday as well as specialised healthcare needs. Its continued focus on women’s health reflects a commitment to improving care experiences and supporting healthier lives at every stage.
View by-
